Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 197

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans

Open access
Wang, Zaiqi, Hall, Stephen D., Maya, Juan F., Li, Lang, Asghar, Ali, Gorski, J. C. · 2003 · British Journal of Clinical Pharmacology

Abstract

Aims Cytochrome P450 2E1 (CYP2E1) is thought to activate a number of protoxins, and has been implicated in the development of liver disease. Increased hepatic expression of CYP2E1 occurs in rat models of diabetes but it is unclear whether human diabetics display a similar up‐regulation. This study was designed to test the hypothesis that human diabetics experience enhanced CYP2E1 expression. Methods The pharmacokinetics of a single dose of chlorzoxazone (500 mg), used as an index of hepatic CYP2E1 activity, was determined in healthy subjects (n = 10), volunteers with Type I (n = 13), and Type II (n = 8) diabetes mellitus. Chlorzoxazone and 6‐hydroxychlorzoxazone in serum and urine were analysed by high‐performance liquid chromatography. The expression of CYP2E1 mRNA in peripheral blood mononuclear cells was quantified by reverse transcriptase‐polymerase chain reaction. Results The mean ± s.d. (90% confidence interval of the difference) chlorzoxazone area under the plasma concentration‐time curve was significantly (P ≤ 0.05) reduced in obese Type II diabetics (15.7 ± 11.3 µg h ml−1; 9, 22) compared with healthy subjects (43.5 ± 16.9 µg h ml−1; 16, 40) and Type I diabetics (32.8 ± 9.2 µg h ml−1; 9, 25). There was a significant two‐fold increase in the oral clearance of chlorzoxazone in obese Type II diabetics compared with healthy volunteers and Type I diabetics. The protein binding of chlorzoxazone was not significantly different between the three groups. In contrast, Type 1 diabetics and healthy volunteers demonstrated no difference in the oral clearance of chlorzoxazone. The urinary recovery of 6‐hydroxychlorzoxazone as a percentage of the administered dose was not different between healthy, Type I and obese Type II diabetics. The elimination half‐life of chlorzoxazone did not differ between the three groups. CYP2E1 mRNA was significantly elevated in Type I and obese Type II diabetics compared with healthy volunteers. The oral clearance of chlorzoxazone, elimination half‐life, Tmax, and Cmax were not significantly influenced by weight, body mass index, serum glucose, serum cholesterol, or glycosylated haemoglobin. Conclusions There was a marked increase in hepatic CYP2E1 activity in obese Type II diabetics as assessed by chlorzoxazone disposition. Increased expression of CYP2E1 mRNA in peripheral blood mononuclear cells was found in both types of diabetes mellitus. Adverse hepatic events associated with Type II diabetes may be in part a result of enhanced CYP2E1 expression and activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2125.2003.01731.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 197

Metadata

Authors
Wang, Z., Hall, S. D., Maya, J. F., Li, L., Asghar, A., & Gorski, J. C.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2003-01
Volume
55
Issue
1
Pages
77-85
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1784102749
Cited by
197
References
1
FWCI
7.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. https://app.cochat.ai/papers/10.1046/j.1365-2125.2003.01731.x
The paper
Wang, Z., Hall, S. D., Maya, J. F., Li, L., Asghar, A., & Gorski, J. C. (2003). Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. British Journal of Clinical Pharmacology. https://doi.org/10.1046/j.1365-2125.2003.01731.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.